Drug Trial Radar · NCT03895801
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Apr 3, 2019
Primary completion
Apr 14, 2021
Study completion Jun 8, 2021
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Conditions
- Granulomatosis With Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
Interventions
IFX-1Drug
intravenously administered
Placebo-IFX-1Drug
intravenously administered
Glucocorticoid (GC)Drug
orally administered
Placebo-Glucocorticoid (Placebo-GC)Drug
orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving Clinical ResponseTime frame: Baseline, Week 16
Locations
76 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Site
Leuven, Belgium
Clinical Site
Liège, Belgium
Clinical Site
Hradec Králové, Czechia
Clinical Site
Prague, Czechia
Clinical Site
Prague, Czechia
Clinical Site
Prague, Czechia
Clinical Site
Angers, France
Clinical Site
Brest, France
Clinical Site
Créteil, France
Clinical Site
Grenoble, France
Clinical Site
Lille, France
Clinical Site
Montpellier, France
Clinical Site
Paris, France
Clinical Site
Paris, France
Clinical Site
Paris, France
Clinical Site
Pessac, France
Clinical Site
Poitiers, France
Clinical Site
Aachen, Germany
Clinical Site
Berlin, Germany
Clinical Site
Cologne, Germany
Clinical Site
Dresden, Germany
Clinical Site
Essen, Germany
Clinical Site
Freiburg im Breisgau, Germany
Clinical Site
Hanover, Germany
Clinical Site
Kirchheim unter Teck, Germany
Clinical Site
Leipzig, Germany
Clinical Site
Ludwigshafen, Germany
Clinical Site
Mannheim, Germany
Clinical Site
Münster, Germany
Clinical Site
Stuttgart, Germany
Clinical Site
Jena, Thuringia, Germany
Clinical Site
Catania, Italy
Clinical Site
Lecco, Italy
Clinical Site
Messina, Italy
Clinical Site
Milan, Italy
Clinical Site
Milan, Italy
Clinical Site
Monza, Italy
Clinical Site
Pavia, Italy
Clinical Site
Pisa, Italy
Clinical Site
Verona, Italy
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.